Summit Therapeutics (SMMT) Other Accumulated Expenses (2019 - 2026)

Summit Therapeutics (SMMT) has reported Other Accumulated Expenses for 8 consecutive years, with $2.6 million the latest figure, recorded in Q2 2026.

• Quarterly Other Accumulated Expenses rose 76.57% year-over-year to $2.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.6 million (up 76.57% YoY) and the FY2025 annual result came in at $2.3 million, up 27.05% from the prior year.
• Other Accumulated Expenses grew to $2.6 million in Q2 2026 per SMMT's latest filing, from $1.1 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for SMMT reached as high as $2.6 million in Q2 2026 and fell as low as $209000.0 in Q3 2022.
• A 5-year average of $1.0 million and a median of $773500.0 in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses tumbled 79.71% — and 2024, when it jumped 150.63%.
• Year by year, Other Accumulated Expenses stood at $662000.0 in 2022, then rose by 8.31% to $717000.0 in 2023, then soared by 150.63% to $1.8 million in 2024, then increased by 27.05% to $2.3 million in 2025, then rose by 14.85% to $2.6 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $2.6 million, $1.1 million, and $2.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.